Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Cipla Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (474)
Cancellation by sponsor (239)
Cancellation or suspension (79)
Prescription medicine registration (47)
Cancellation for failure to pay annual charge (17)
Australian public assessment report (AusPar) (5)
Prescription medicine decision summary (4)
Prescription medicine evaluation (1)

Date

2026 (23)
2025 (98)
2024 (73)
2023 (99)
2022 (70)
2021 (65)
2020 (112)
2019 (18)
2018 (68)
2017 (104)
2016 (27)
2015 (33)
2014 (13)
2013 (6)
2012 (4)
2011 (6)
2010 (16)
2009 (4)
2008 (3)
2007 (5)
2006 (2)
2005 (2)
2004 (2)
2003 (3)
2002 (2)
2001 (3)
2000 (1)
1999 (2)
1998 (1)
1996 (1)

Search

Sponsor content

866 result(s) found, displaying 101 to 110

CIPLA IMATINIB ADULT imatinib (as mesilate) 100 mg capsules blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
CIPLA IMATINIB ADULT imatinib (as mesilate) 400 mg capsules blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
CIPLA ESCITALOPRAM escitalopram (as oxalate) 10 mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
CIPLA ESCITALOPRAM escitalopram (as oxalate) 20 mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
LAMOTRIGINE ACTAVIS lamotrigine 200mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
LAMOTRIGINE ACTAVIS lamotrigine 100mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
LAMOTRIGINE ACTAVIS lamotrigine 50mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
LAMOTRIGINE ACTAVIS lamotrigine 25mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
CIP ABIRATERONE (Cipla Australia Pty Ltd)

27 June 2025

Prescription medicine registration

Active ingredients: abiraterone acetate.
CIP NINTEDANIB (Cipla Australia Pty Ltd)

16 June 2025

Prescription medicine registration

Active ingredients: nintedanib esilate.

Pages

First page
Previous page
…
Page 7
Page 8
Page 9
Page 10
Current page 11
Page 12
Page 13
Page 14
Page 15
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.